The abstract is read at the publisher; the summary is JClub's.
Mechanism-based interventions and emerging irAE biomarkers are advancing precision toxicity control for immune checkpoint inhibitor therapy, aiming to better manage immune-related adverse events.
- Why it matters: Immune-related adverse events can interrupt treatment and constrain effective combination strategies, while broad immunosuppression may undermine antitumor immunity and miss irAE-specific biology.
- What they did: This review synthesizes targeted approaches—such as cytokine blockade, tissue-restricted immunomodulation, and targeting pathogenic lymphocytes or humoral pathways—alongside biomarker advances for personalized risk assessment and intervention selection.
- The result: The work outlines a translational and clinical roadmap, from clinically useful irAE taxonomies to biomarker-guided trials, to support implementation of precision toxicity control in practice.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.